StockDrifts LogoStockDrifts

Dongkuk Pharmaceutical 086450

Company
동국제약Dongkuk Pharmaceutical
Insiders
0
Buys
0
Total Value
—
Avg Return
—
Last Filing
2025-10-14

Dongkuk Pharmaceutical (086450) has 0 disclosed insider purchases and 0 disclosed disposals on record, filed by 0 distinct insiders. The earliest filing StockDrifts holds for Dongkuk Pharmaceutical is dated 2024-04-04; the most recent is 2025-10-14.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2025-10-14SELL전환등
디케이앤컴
DK&COM
--346.7K₩18,320-12.2%₩6.4B ($4.4M)
2025-10-14BUY기타
디케이앤컴
DK&COM
-346.7K₩18,320+12.2%₩6.4B ($4.4M)
2024-04-04BUY자사주상여금
오흥주
Heungju Oh
vice president6.0K₩16,620+23.6%₩100M ($69K)

Frequently asked questions

Who has been buying Dongkuk Pharmaceutical stock?
0 distinct insiders have filed 0 disclosed insider purchases in Dongkuk Pharmaceutical (086450), most recently on 2025-10-14. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Dongkuk Pharmaceutical have?
Dongkuk Pharmaceutical has 0 buy-side and 0 sell-side disclosures on record, spanning 2024-04-04 to 2025-10-14.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.